Investigational drug · Phase 2
VTX2735
Also called: LY5625574
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent Pericarditis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "VTX2735"
First trial start
2025
Jan 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VTX2735", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Pericarditis
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "VTX2735" as an intervention, largest first.
Zomagen Biosciences Ltd.Industry
NCT06836232 · 50 participants (planned) · Start Jan 28, 2025 · Primary completion Oct 2027
Drug: VTX2735; VTX2735 and 3 more · For: Recurrent Pericarditis
Sites: La Jolla, California; Orange, California; Saint Augustine, Florida · 20 sites in all
Zomagen Biosciences Ltd.Industry
NCT05812781 · 7 participants · Start Mar 18, 2023 · Primary completion Mar 6, 2024
Drug: VTX2735; VTX2735 · For: Cryopyrin Associated Periodic Syndrome
Sites: San Diego, California; Columbus, Georgia
Newest research
PubMed records naming it or its code names, newest first.
- Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options.
Imazio M, Collini V, Venturelli F, et al. · Expert Opin Emerg Drugs 2026
- Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates.
Zhen D, Liu C, Sun X, et al. · Front Pharmacol 2026
Also in development for Recurrent Pericarditis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.